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Abstract
Background: Transmission of the prion disease bovine spongiform encephalopathy (BSE) occurred accidentally to
cattle and several other mammalian species via feed supplemented with meat and bone meal contaminated with
infected bovine tissue. Prior to United Kingdom controls in 1996 on the feeding of mammalian meat and bone
meal to farmed animals, the domestic chicken was potentially exposed to feed contaminated with the causal
agent of BSE. Although confirmed prion diseases are unrecorded in avian species a study was undertaken to
transmit BSE to the domestic chicken by parenteral and oral inoculations. Transmissibility was assessed by clinical
monitoring, histopathological examinations, detection of a putative disease form of an avian prion protein (PrP) in
recipient tissues and by mouse bioassay of tissues. Occurrence of a progressive neurological syndrome in the
primary transmission study was investigated by sub-passage experiments.
Results: No clinical, pathological or bioassay evidence of transmission of BSE to the chicken was obtained in the
primary or sub-passage experiments. Survival data showed no significant differences between control and
treatment groups. Neurological signs observed, not previously described in the domestic chicken, were not
associated with significant pathology. The diagnostic techniques applied failed to detect a disease associated form
of PrP.
Conclusion: Important from a risk assessment perspective, the present study has established that the domestic
chicken does not develop a prion disease after large parenteral exposures to the BSE agent or after oral exposures
equivalent to previous exposures via commercial diets. Future investigations into the potential susceptibility of
avian species to mammalian prion diseases require species-specific immunochemical techniques and more refined
experimental models.
Background
The transmissible spongiform encephalopathies (TSE) or
prion diseases are fatal neurodegenerative disorders
characterised by vacuolation, neuronal loss, gliosis and
accumulation of an abnormal form (PrP
Sc)o fan a t u r a l
host encoded “prion” protein (PrP
c) [1].
Naturally occurring TSE are reported exclusively in
mammals. Among non-human species they include
scrapie in sheep and goats, chronic wasting disease in
deer and elk, transmissible mink encephalopathy in
farmed mink and bovine spongiform encephalopathy
(BSE) in cattle and other species. BSE, initially diagnosed
in Great Britain in domestic cattle [2]) and presenting as
an extended common source epidemic, was shown to be
transmitted via feeding commercial rations containing
meat and bone meal (MBM) [3]. Unique among animal
TSE, BSE was also transmitted via feed to several other
captive bovid species [4] and through dietary inclusion
of infected cattle tissues to a range of felids, both
domestic [5] and zoo kept species [4]. Although the full
extent of this species susceptibility to the BSE agent,
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known in the early stages of the epidemic in cattle, the
involvement of MBM as the primary vector of infection
inevitably raised concerns regarding the potential infec-
tion of other domesticated livestock, including non-
ruminant species [7,8]. Ruminant-derived MBM was
used as a component of domestic poultry rations until
the United Kingdom ban on feeding mammalian MBM
to all farm animals in April 1996 [9], providing oral
exposure of this species to BSE infectivity at concentra-
tions potentially similar to those promoting the bovine
epidemic.
Neither at the time of the instigation of this study
(June 1990) nor since, have there been published reports
of naturally occurring avian TSE or successful transmis-
sion of a TSE to an avian species.
The present study examines the transmissibility of the
BSE agent to domestic chickens by parenteral and oral
routes of exposure. Transmission was initially evaluated
on the basis of clinical monitoring of recipients for neu-
rological disease, histopathological examinations for
encephalopathic changes, and detection of aggregates of
a proteinase K (PK) resistant form of the putative dis-
ease form (PrP
res)o fa na v i a np r i o np r o t e i n( P r P
c)i n
brain tissue, equivalent to scrapie-associated fibril (SAF)
extraction in the diagnosis of mammalian prion diseases.
Immunohistochemistry (IHC) for the detection of a dis-
ease specific form of the prion protein (PrP
d)w i t h o u t
the use of proteases was also attempted on brain using
mammalian derived antibodies to PrP. In view of the
empirical nature of this approach further work was
undertaken to identify mammalian PrP antibodies that
were most likely to detect avian PrP. In addition, Wes-
tern immunoblotting for the detection of PrP
res was
undertaken similarly. Mouse bioassays for detection of
tissue infectivity were also performed.
In the course of the primary transmission study a pro-
gressive neurological syndrome was observed in some
male chickens of both parenteral and oral exposure
groups without pathological evidence of a TSE. This
syndrome was further investigated by sub-passage
experiments.
Methods
All procedures were carried out in accordance with the
Animal (Scientific Procedures) Act 1986, under Licence
from the UK Government Home Office (Licence num-
bers: 70/3994, 70/5257).
Inocula
For the primary transmission study an inoculum was
prepared as a 10% w/v homogenate, in saline, of pooled
caudal medulla oblongata from two clinical BSE cases.
These cases were confirmed by the statutory diagnostic
methods in use at the time of their death in 1989: histo-
pathological examination of the brain for spongiform
encephalopathy and detection of SAF by negative-con-
trast transmission electron microscopy. Primary trans-
missions from brainstem of each of the donor cattle to
inbred mice provided uniform disease characteristics
consistent with the agent of BSE from previous sources
(see cows 5 and 6 respectively from [10]). The unifor-
mity of incubation periods obtained in the mice with
those of the equivalent dilution of previously titrated
inocula [11] suggested a titre for the present inoculum
of 10
5 intracerebral ID50 mouse infectious units per
gram.
For the sub-passage experiments in chickens three
inocula were prepared, all comprising a 10% w/v homo-
genate of pooled brain and sciatic nerve in saline. One
inoculum pool was derived from all parenterally exposed
chickens which exhibited the progressive neurological
syndrome, the second from orally exposed chickens
which exhibited the syndrome, and the third from clini-
cally normal, saline inoculated control chickens. The
same inocula pools were used for the inoculation of
mice.
Animals and exposures
Hybrid day old specific pathogen free (SPF) chicks were
sourced for the study. For the primary transmission
study 12 chicks were inoculated intracranially (i.c.) with
50 μl of the homogenate at 1 day old and then intraperi-
toneally (i.p.) with 1 ml at 2 weeks of age. To simulate
the potential dietary exposure of domestic chicken to
BSE contaminated feed, 11 chickens were inoculated
with 5 g of pooled BSE affected brain tissue into the dis-
tal oesophagus/crop by gavage on 3 occasions, at 4, 5
and 6 weeks of age. This dose approximates to the aver-
age maximum daily intake of MBM at 15% incorpora-
tion into the diet for the first month of life. A further
14 chicks were inoculated i.c. with 50 μl of a 10% saline
solution at 1 day old, then i.p. with 1 ml saline at 2
w e e k so fa g ea n ds e r v e da sa g em a t c h e dc o n t r o l sf o r
both the parenteral and oral primary exposure studies.
For the sub-passage experiments three groups of day-
old SPF chicks were inoculated i.c. with 50 μl of each
test inoculum. Fifteen received inoculum derived from
parenterally exposed chickens exhibiting the neurologi-
cal syndrome; sixteen received inoculum from orally
exposed chickens exhibiting the syndrome and 13
received inoculum from clinically normal, saline inocu-
lated control chickens. Twelve chicks were inoculated i.
c. with saline only.
All chicks used in the primary exposure study were
housed initially in experimental groups arranged as
separate cage racks, with each cage containing an entire
group. As the chicks grew the number per cage was
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were housed singly. Chickens used in the sub-passage
study were housed in a free range floor system.
Prior to the enforcement of the ban on feeding mam-
malian MBM to all farmed animals and for the first 4.5
months of the primary exposure, chicks were reared on
a commercial diet containing a premixed MBM compo-
nent (0.4% by weight) some of which may, in retrospect,
have contained ruminant-derived protein. Thereafter the
commercial ration was replaced with a home-mixed,
MBM free ration which was fed ad libitum.F o rt h e
sub-passage experiment all chickens were reared and
maintained on the same home-mixed ration, fed ad
libitum.
All chickens were monitored clinically for up to 5
years post inoculation (p.i.) when they were killed and
examined post-mortem. Chickens developing intercur-
rent disease were killed if welfare was compromised.
Clinical monitoring
The chickens were inspected daily for signs of abnorm-
ality by attendants at the time of husbandry duties, such
as feeding and cleaning. In the primary study a veterin-
ary clinician conducted a bi-weekly passive observation
for 15 min per group. Any indications of abnormality
were supported by an individual clinical examination
that included testing of neurological reflexes and assess-
ment of locomotion. These examinations were also con-
ducted shortly before culling. Body weight, weekly food
consumption and behaviour (time spent lying, standing,
active, idle, preening or eating) were recorded. Weekly
food consumption was recorded on four occasions. In
the sub-passage study, the same methods were used but
the passive clinical observations were conducted weekly.
Statistical analysis was performed using the Statistica
package (version 10, Statsoft Ltd., Bedford, UK), which
included analysis of variance of selected signs and survi-
val analysis (chickens culled for welfare reasons were
censored).
Post-mortem sampling
From all chickens in the primary exposure study the
frontal cerebrum, sciatic nerve, skeletal muscles (pec-
toral and hindlimb adductors), liver, spleen, kidney,
small intestine and bursa of Fabricius were aseptically
sampled and stored frozen for possible subsequent
bioassay studies. A segment of cervical spinal cord was
taken for SAF extraction and stored at -20°C. The brain,
spinal cord, sciatic nerve, pectoral and adductor muscles
and bursa of Fabricius were also sampled for histopatho-
logical and immunohistochemical examinations. Addi-
tional tissues were sampled as gross post-mortem
findings required, particularly where initial observations
indicated changes potentially causal in intercurrent
disease deaths. Central nervous system tissue was placed
into 10% formol saline and other tissues were fixed in
neutral buffered 10% formalin. After post-mortem
removal of the cervical spinal cord segment the remain-
ing spinal cord was fixed in situ within the vertebral
canal to avoid possible fresh dissection damage to the
cord and was later removed for further sampling. Chick-
ens which died or were killed because of intercurrent
disease before the planned termination of the study
were examined similarly.
From all chickens in the sub-passage study, selected
fresh tissues were aseptically sampled post-mortem,
including frontal cerebrum, cervical and thoracic spinal
cord, sciatic nerve, pectoral muscle, adductor muscle,
ischiotibial muscle, heart, liver, spleen, kidney, small
intestine, and bursa of Fabricius. The range of tissues
sampled for histopathological examination encompassed
those for the primary exposure study. Chickens that
died or were killed because of intercurrent disease
before the planned kill date were examined similarly.
Histopathology
Blocks were prepared from coronal sections of the brain
at eight levels, approximating to selected levels from an
atlas of the chicken brain (levels 9,10,12,14,17,19, 23 and
24, see [12]) to achieve representation of all major brain
regions. Transverse blocks of spinal cord (cervical, thor-
acic and lumbar) were also prepared. Sciatic nerve and
skeletal muscles were blocked transversely and longitud-
inally. Visceral tissue samples were blocked routinely.
Tissues were fixed for 3-5 days and then processed
o v e r n i g h to na na u t o m a t i ctissue processor before
embedding in paraffin wax. Sections 5 μmt h i c kw e r e
cut and stained by a modification of the routine haema-
toxylin and eosin method [13]. Muscles were stained
using a collagen and elastin method.
SAF examination
Cervical spinal cord samples were prepared for SAF
examination by an extraction technique as described
previously [14,15]. The resulting negatively stained sam-
ples were examined in either a Phillips 410 or a CM10
transmission electron microscope at magnifications
greater than 25,000. A positive result was recorded if
one or more fibrils within the original definition [16]
were identified. Where fibrils were not detected each
sample was examined for 20 min before being declared
negative. Thirty-three samples from the primary expo-
sure study were examined: 10/12 parenterally exposed
chickens, 11/11 orally exposed chickens, and 12/14 con-
trol chickens. Thirty-six samples from the sub-passage
study were examined similarly: 14/15 chickens inocu-
lated with nervous tissue from parenterally exposed
chickens in the primary exposure study, 10/16 chickens
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chickens, and 12/13 chickens inoculated with nervous
tissue from saline controls.
Immunohistochemistry
A series of IHC examinations were carried out on cen-
tral nervous system tissues for the detection of a puta-
tive disease form of an avian prion protein.
Interpretation of immunodetection was necessarily made
without the benefit of an avian TSE/prion disease posi-
tive control. Controls included BSE affected bovine
brainstem, BSE and scrapie affected sheep brainstem,
omission of the primary antibody, substitution of the
primary antibody with normal rabbit serum or immuno-
globulin (Ig) G from the species in which each antibody
was raised, and brainstem from normal cattle and sheep.
Initially, frontal cerebrum, cerebellum/medulla and
spinal cord from one control (ID: 962) and one orally
exposed (ID: 976) chicken from the primary exposure
study were immunolabelled with antibodies IA8 and 971
F (Table 1). Subsequently, the same tissues from up to
three chickens per treatment group (ID: 379, 390, 715,
853, 866, 928, 929, 946) in the sub-passage study were
immunolabelled with antibodies 1B3, F99, IA8, L42,
R145 and Rb486 (Table 1).
Investigations were also carried out which aimed to
maximise the chances of detecting PrP
d. First, brain
blocks from both the primary exposure and sub-passage
studies were selected in which mild vacuolar changes
had been detected. Secondly, since there are currently
no commercially available antibodies raised against the
chicken prion protein, epitope sequences for 24 ovine
and bovine anti-PrP antibodies were aligned to the
National Center for Biotechnology Information (NCBI)
r e f e r e n c es e q u e n c ef o rt h ec h i c k e np r i o np r o t e i n
(NP_990796.1) to select potentially appropriate antibo-
dies. Alignments were performed using the European
Bioinformatics Institute European Molecular Biology
Open Software Suite (EBI EMBOSS) pairwise alignment
algorithms [26] with a gap penalty of 25 to ensure full-
length matches. For each alignment the percent identity
and percent similarity to the full-length of the epitope
sequence was calculated. Two antibodies (R568 and 6
C2) were identified which had 100% identity to epitopes
on the chicken prion protein. These antibodies were
then used in further IHC examinations in parallel with
antibodies R145, 2 G11 and P4.
Brain samples from six exposed chickens, which had
displayed neurological signs and which had the longest
survival times in their treatment group (ID: 388, 963,
972, 985, 977, 990) (Table 2), were selected for IHC
examination. For two of the chickens (ID: 977, 990) for
which both fixed and frozen brain was available, Wes-
tern immunoblotting examinations were also conducted
(see below). Brains samples from two healthy unexposed
chickens were included as negative controls.
Western immunoblotting (WB)
For the detection of PrP
res by WB in brain tissue, from
one orally exposed (ID: 977), one intracerebrally inocu-
lated (ID: 990) (from the primary inoculation experi-
ment) and two healthy non-exposed chickens, the
commercially available BioRad TeSeE™ Western blot
(BioRad, Marnes le Coquette, France) was used accord-
ing to manufacturers instructions with a minor change.
The test was modified by replacing the kit primary anti-
body with monoclonal antibody 6C2 [24]. No avian
BSE-positive control tissue was available for profile com-
parison but two brain samples from healthy, non-inocu-
lated chickens were included as negative controls.
Mouse bioassays for detection of infectivity
Three pooled inocula comprising brain and sciatic nerve
from selected primary parenterally inoculated (ID: 980,
983, 984, 985), orally inoculated (ID: 965, 969, 976, 978)
and saline inoculated control (ID: 952, 953, 957, 962)
Table 1 PrP antibodies used for immunohistochemistry
Antibody Mono/Polyclonal Immunogen raised against Dilution Reference
1B3 Polyclonal Mouse ME7 scrapie SAF 1/1000 [17,18]
IA8 Polyclonal Mouse ME7 scrapie SAF 1/2500 [17]
971F Polyclonal Bovine PrP 221-232 1/2500 [18]
F99 Monoclonal Ovine PrP 220-225 1/4000 and 1/8000 [19]
P4 Monoclonal Ovine PrP 89-104 1/12000 [20]
R145 Monoclonal Bovine PrP 221-232 1/100 and 1/500 [21]
L42 Monoclonal Ovine PrP 145-163 1/250 [22]
Rb486 Polyclonal Bovine PrP 240-254 1/2500 [22]
R568 Polyclonal Ovine PrP 126-143 1/100 [23]
6 C2 Monoclonal Ovine PrP 114-120 1/100 [24]
2 G11 Monoclonal Ovine PrP 146-R
154R
171-182 (recognising R
151-R
159) 1/400 [25]
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Page 4 of 13chickens respectively (Table 2), were assayed in a panel
of five inbred mouse strains (Rlll (Sinc
s7), C57BLJ6
(Sinc
s7), VM (Sinc
p7), IM (Sinc
p7) and an F1 cross of
C57BLJ6 and VM) according to standard procedures
[10]. Using 20 mice per strain group, each mouse was
injected with 0.02 ml i.c. and 0.1 ml i.p. of a single
inoculum. Mice were clinically monitored from 250 days
p.i. and the clinical end-point, when the mice showed
Table 2 Individual data for chickens in primary exposure study
Bird
Identification
Inoculum Route of
exposure
Sex Survival time
(days)
Experimental outcome (E/D)
a and occurrence of syndromes
(M/N)
b
986 Bovine BSE Parenteral
c f 65 (E) Neurological signs, NSL
988 Bovine BSE Parenteral f 273 (D)/NSL
982 Bovine BSE Parenteral m 274 (D)/NSL
981 Bovine BSE Parenteral f 378 (E) Egg peritonitis
983
d Bovine BSE Parenteral m 664 (E) Acute onset (M)
980
d Bovine BSE Parenteral m 1302 (D)/NSL (M/N)
984
d Bovine BSE Parenteral m 1486 (D)/NSL (M)
989 Bovine BSE Parenteral f 1780 (D) Ovarian adenocarcinoma (N)
979 Bovine BSE Parenteral f 1804 (E) Ovarian adenocarcinoma (N)
987 Bovine BSE Parenteral f 1841 Terminal kill/NSL (M/N)
985
§ Bovine BSE Parenteral m 1841 Terminal kill/NSL (M/N)
990 Bovine BSE Parenteral f 1843 Terminal kill/NSL (M/N)
966 Bovine BSE Oral f 390 (E) Hepatitis
970 Bovine BSE Oral f 573 (E) Weight loss
976
d Bovine BSE Oral m 1230 (E) (M)
978
d Bovine BSE Oral m 1413 (E) (M)
969
d Bovine BSE Oral m 1555 (E) Collapse (M)
965
d Bovine BSE Oral m 1601 (E) (M)
967 Bovine BSE Oral f 1808 (D) Ovarian adenocarcinoma
971 Bovine BSE Oral f 1830 Terminal kill/NSL (N)
968 Bovine BSE Oral f 1830 Terminal kill/NSL (N)
977 Bovine BSE Oral m 1834 Terminal kill/NSL (M)
972 Bovine BSE Oral f 1834 Terminal kill/NSL (N)
959 Saline Parenteral f 222 (D)
958 Saline Parenteral m 395 (E) Weight loss
955 Saline Parenteral m 757 (D)
960 Saline Parenteral m 862 (E) Weight loss/NSL
956 Saline Parenteral m 1037 (D)/NSL
964 Saline Parenteral m 1037 (E) Neurological signs/NSL
951 Saline Parenteral m 1225 (E) Neurological signs/NSL
961 Saline Parenteral f 1310 (E) Egg peritonitis
954 Saline Parenteral f 1528 (E) Weight loss/NSL
963 Saline Parenteral f 1547 (D) Ovarian adenocarcinoma (N)
953
b Saline Parenteral m 1837 (D) Meningoencephalitis (N)
952
b Saline Parenteral f 1868 Terminal kill/NSL
962
b Saline Parenteral f 1868 Terminal kill/NSL (N)
957
b Saline Parenteral f 1868 Terminal kill/splenomegaly/meningo-encephalitis (N)
m male; f female
aE euthanasia due to compromised welfare; D found dead
bM motor disturbance syndrome; N narcolepsy
cintracranial and intraperitoneal
NSL no significant lesions at necropsy
dDonor chicken for sub-passage studies
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mined according to established criteria for calculating
incubation period [27]. End points for termination of
assays were 900 days for the RIII, VM and IM mice, 950
days for C57BL mice, and 800 days for the F1 cross
mice. Mice surviving to these end-points were killed and
their brains removed and processed routinely for histo-
pathological examination for evidence of a TSE-like
encephalopathy and immunohistochemical examination
for PrP
d using rabbit antiserum Rb486 as described pre-
viously [28]. Mice which died or were killed because of
intercurrent disease before the end point were examined
similarly.
Results
Individual animal results of the primary and sub-passage
transmission experiments are given in Tables 2 and 3.
Survival analysis
Of the 93 chickens in the study 72 (77.42%) were
included in the Kaplan-Meier survival analysis while 21
(22.58%) were censored. No significant difference was
detected between treatment groups in the primary
exposed (P = 0.34) (Figure 1) or sub-passage (P = 0.79)
(Figure 2) experiments. Overall, the survival times for
the primary exposure and sub-passage groups were not
significantly different (P = 0.74).
Clinical assessments
A number of chickens were lost to intercurrent diseases
which included ovarian adenocarcinoma, sometimes
with transcoelomic metastases and egg peritonitis in
female chickens. Impaction of the crop also occurred.
Degenerative joint disease featured in a proportion of
long-surviving chickens. These disorders did not mani-
fest with neurological signs and occurred in exposed
and control chickens in both the primary and sub-pas-
sage experiments (Tables 2 and 3).
Body weight and behavioural observations were ana-
lysed using analysis of variance with treatment group
and sex as factors. The males were found to be signifi-
cantly heavier than the females (P < 0.05) but no signifi-
cant differences between treatment groups were
detected. On the last of the weekly occasions when food
consumption was recorded, a highly significant (P <
0.05) treatment effect was found. In this week the par-
entally and orally exposed chickens ate significantly less
than the controls, 28% and 37% respectively. No signifi-
cant treatment effects were found on the specific beha-
vioural features recorded but it was apparent that males
s p e n ts i g n i f i c a n t l ym o r et i m ei d l ec o m p a r e dw i t h
females.
Two clinical neurological syndromes were recognised
in the primary experiments. First, a syndrome associated
with feeding: chickens would appear to develop an epi-
sodic loss of consciousness resembling narcolepsy. This
occurred in both exposed and control chickens. More
female chickens displayed this behaviour than males
(Table 4) and the episodes in females tended to be more
pronounced than those displayed by male chickens.
The signs observed were evident during a period of
feeding activity (sometimes this may have been simu-
lated or “sham feeding”) when affected chickens would
appear to become semi-conscious, slowly adopting ster-
nal and then lateral recumbency. They then remained
still, apart from occasional weak wing or leg movements,
for up to three minutes before suddenly and sponta-
neously regaining full consciousness. On recovery from
an episode, affected chickens would often resume feed-
ing immediately, a practice that then appeared to evoke
r e p e t i t i o no ft h es y n d r o m e( s e ea d d i t i o n a lf i l e1 :9 7 9
NS, which shows one of these episodes during feeding).
Secondly, a motor disturbance syndrome (MDS) was
observed in four parenterally exposed and four orally
exposed male chickens. None of the female exposed or
control chickens that survived to the terminal kill devel-
oped the syndrome (Table 4).The first case (ID: 983)
presented at 1,302 days p.i. and others subsequent
through to the terminal kill at 1,834 days p.i. In seven of
the chickens the disorder was slowly progressive, while
in one chicken there was an acute onset of clinical signs
(ID: 983). Clinical signs associated with the disorder
variably included: ataxia, deficits in righting reflexes, bal-
ance deficits, tremor, abduction of the leg to maintain
standing posture, voice change, immobility, tendency to
sternal and/or lateral recumbency, partial closing of the
eyelids, and rapid dilatation and constriction of the
pupil (see additional file 2: 980 MDS, which shows a
chicken with balance deficits).
In the sub-passage experimental groups a number of
chickens in all groups were lost to a similar range of
intercurrent diseases as in the primary exposure experi-
ment and these occurred to a similar extent in exposed
and control chickens.
A number of chickens also developed a range of neu-
rological signs including ventroflexion of the neck,
abnormal head movements, ataxia, balance deficits,
depressed mentation and weakness/collapse, resembling
some aspects of the MDS, but the narcolepsy-like syn-
drome was not observed.
Histopathology
Overall, no significant or systematic degenerative pathol-
ogy was identified in the brain, spinal cord, sciatic nerve
or skeletal muscle tissues of any of the chickens. Rela-
tively sparse multiple large vacuoles were observed in
the superficial grey matter of the optic tectum, white
matter tracts of the brainstem and cerebellar white
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Page 6 of 13Table 3 Individual data for recipient chickens in sub-passage study
Bird
identification
Primary exposure group source of
inoculum
Sex Survival time
(days)
Experimental outcome (E/D)
b
387 Parenteral BSE m 111 (E) Pecking trauma
391 Parenteral BSE f 131 (E) Neurological signs/NSL
392 Parenteral BSE f 353 (E) Prolapsed oviduct
385 Parenteral BSE m 916 (E) Neurological signs/NSL
384 Parenteral BSE m 1059 (D) Pneumonia
390 Parenteral BSE f 1217 (E) Ovarian adenocarcinoma
393 Parenteral BSE f 1229 (E) Ovarian adenocarcinoma
395 Parenteral BSE f 1266 (E) Ovarian adenocarcinoma
379 Parenteral BSE m 1377 (E) Neurological signs/NSL
394 Parenteral BSE f 1728 (D) Ovarian adenocarcinoma
389 Parenteral BSE f 1728 (E) Ovarian adenocarcinoma
376 Parenteral BSE m 1834 Terminal kill/NSL
378 Parenteral BSE m 1834 Terminal kill/NSL
382 Parenteral BSE m 1834 Terminal kill/NSL
388 Parenteral BSE m 1834 Terminal kill/NSL
945 Oral BSE f 154 (E) Pecking injuries
943 Oral BSE f 209 (E) Pecking injuries
930 Oral BSE m 353 (E) Crop impaction
931 Oral BSE m 353 (E) Crop impaction
942 Oral BSE f 448 (E) Egg peritonitis
928 Oral BSE m 891 (E) Musculoskeletal/neurological signs
935 Oral BSE f 940 (E) Wing fracture
937 Oral BSE f 951 (E) Musculoskeletal/neurological signs
929 Oral BSE m 967 (E) Neurological signs
927 Oral BSE m 1258 (D) Previous neurological signs.
946 Oral BSE f 1483 (E) Egg peritonitis
939 Oral BSE f 1636 (D) Ovarian adenocarcinoma
933 Oral BSE m 1833 Terminal kill/degenerative joint disease
941 Oral BSE m 1833 Terminal kill/degenerative joint disease
936 Oral BSE f 1833 Terminal kill/mild egg peritonitis
926 Oral BSE m 1833 Terminal kill/degenerative joint disease
870 Parenteral saline control f 156 (E) Prolapsed oviduct
860 Parenteral saline control f 209 (E) Pecking trauma
865 Parenteral saline control m 328 (E) Crop impaction
858 Parenteral saline control m 513 (E) Suppurative keratitis
862 Parenteral saline control m 1206 (D) Possible ataxia/NSL
853 Parenteral saline control m 1219 (E) Neurological signs/NSL
866 Parenteral saline control m 1343 (E) Musculoskeletal/neurological signs/NSL
856 Parenteral saline control f 1372 (E) Neurological signs/NSL
851 Parenteral saline control m 1620 (D) Possible neurological signs/NSL
855 Parenteral saline control m 1643 (D) Musculoskeletal/neurological signs/NSL
863 Parenteral saline control m 1655 (E) Musculoskeletal/neurological signs/degenerative joint
disease
871 Parenteral saline control f 1666 (D) Ovarian adenocarcinoma
867 Parenteral saline control f 1835 Terminal kill/degenerative joint disease
710 Saline
a m 351 (E) Musculoskeletal/neurological signs.
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Page 7 of 13matter of both control and exposed chickens. Vacuolar
change was also often seen in the spinal cord grey mat-
ter but occurred in both control and exposed chickens.
SAF examination
No TSE associated fibrils could be detected in any of
the spinal cords from inoculated or control chickens
from which material was examined.
Immunohistochemistry
Each antibody tested showed patterns of particulate or
diffuse immunolabelling, but similar patterns and inten-
sities of labelling for individual antibodies occurred in
both control and BSE exposed chickens. For example,
R486 immunolabelled multi-focal neuropil areas in the
spinal central grey matter, R586 showed diffuse high
background immunolabelling with intense labeling of
Figure 1 Kaplan-Meier survival data for primary exposure study. Survival data is shown for chickens challenged with BSE parenterally
(orange), orally (blue) and the saline-challenged control group (black).
Table 3 Individual data for recipient chickens in sub-passage study (Continued)
704 Saline
a f 446 (E) Prolapsed oviduct
712 Saline
a m 730 (E) Intermittent haemorrhage from comb
708 Saline
a f 761 (E) Coelomic mass
715 Saline
a m 968 (E) Neurological signs
707 Saline
a f 1439 (D)Ovarian adenocarcinoma
706 Saline
a f 1448 (E) Ovarian adenocarcinoma
705 Saline
a f 1721 (E) Egg peritonitis
714 Saline
a m 1729 Terminal kill/multifocal non-suppurative
meningoencephalitis
709 Saline
a m 1729 Terminal kill/NSL
711 Saline
a m 1730 Terminal kill/NSL
713 Saline
a m 1730 Terminal kill/NSL
All recipient chickens were exposed intracranially
aSaline controls, not derived from primary transmission groups
m male; f female
bE euthanasia due to compromised welfare; D found dead
NSL no significant lesions at necropsy
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Page 8 of 13neuronal perikarya and neuropil of some strata. With
other antibodies including R145 the predominant label-
ling was a widespread fine particulate form. Similar
labelling was observed with antibody 6C2 and remained
in tissue sections where the primary antibody (6C2) was
omitted or replaced with mouse IgG.
IA8 also immunolabelled the spinal dorsal horn grey
matter and spinal ganglia perikarya and IB3 and L42
immunolabelled populations of neurons.
Western immunoblotting
Protein bands were detected by mAb 6C2 in the non-PK
treated chicken samples as well as the known positive
bovine BSE and ovine scrapie control samples, however
the molecular mass of the bands detected in the chicken
samples was too great to be compatible with the
sequence-based estimate for chicken PrP. Following PK
digestion, PrP
res was only detected in the positive BSE
and scrapie control samples and not in samples from
inoculated or non-inoculated chickens.
Mouse bioassay
There was no confirmatory evidence of infectivity in any
of the pools. A number of mouse brains showed vacuo-
lar changes, e.g. in the corpus callosum, which are com-
monly seen in aged wild-type mice [29].
Discussion
No evidence of the susceptibility of chickens to BSE
emerged from these primary inoculation or sub-passage
experiments. Kaplan-Meier survival data showed no sig-
nificant differences between control and treatment
groups. No pathology, which in mammals would have
significance in relation to TSE, was identified in any of
the chickens. Although there have been no substantiated
reports of naturally occurring avian prion disease,
Schoon et al. [30] described three cases of interest in
red-necked ostriches (Struthio camelus)i nt w oz o o si n
northern Germany, in 1986, 1988 and 1989. These
birds, and two subsequent cases in 1992-1993, displayed
progressive clinical signs of a nervous disorder with
Table 4 Incidence of cases of feeding-associated
narcolepsy and motor disturbance syndrome (MDS) by
sex
Narcolepsy
a MDS
a
Treatment group m f m f
Parenterally exposed 2/3 4/4 4/4 0/4
Orally exposed 0/1 3/3 5/5 0/4
Control 1/1 5/6 0/5 0/6
m male; f female
aNumber of chickens affected/number of chickens surviving at the time of
onset of the syndrome
Figure 2 Kaplan-Meier survival data for sub-passage study. Survival data is shown for chickens challenged intracranially with inoculum
made from parenterally (orange), orally (blue) BSE-challenged chickens exhibiting the neurological syndrome, from clinically normal saline-
challenged control chickens (black) of the primary exposure study and a separate intracranially saline-challenged control group (grey).
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Page 9 of 13ataxia, changes to balance, uncoordinated movements
during feeding and had vacuolar changes in the brain-
stem, but transmission studies failed to establish the
nature of the disorder [31].
The two clinically defined syndromes observed in the
present study appear to be more of interest in terms of
the husbandry and experimental circumstances than of
significance to the study aims.
The narcolepsy-like behaviour seemed to be associated
with the approach of food satiety, but the behaviour was
not observed in the sub-passage study when the housing
was a free range floor system, suggesting that prolonged
cage confinement in the primary study may have played
a role.
Although in the primary study the MDS was observed
only in exposed chickens, insufficient male control
chickens survived to the terminal kill to determine
whether there was a statistically significant correlation
between exposure to BSE and the development of MDS,
or whether MDS was a disorder peculiar to the males of
the strain of chicken used in the experiment.
Similar signs to those of the MDS observed in the pri-
mary exposure study also occurred in each group in the
sub-passage study, but the more frequent occurrence of
such cases in the chickens that received tissues from the
saline control chickens of the primary study than recipi-
ents of tissues from BSE exposed chickens, argues
strongly against any relationship to exposure to the BSE
agent.
Neither the feeding associated narcolepsy nor MDS
have previously been reported in commercially farmed
domestic chickens. However, these syndromes were
observed in circumstances that were themselves unu-
sual. The lifespan of commercially farmed chickens is
usually approximately 45 days (broiler chickens) to 18
months (laying chickens) and their behaviour is not
scrutinized in detail. Since neither of the syndromes or
any other intercurrent diseases were observed in chick-
ens less than 2 years of age it is possible that the
observed behavioural abnormalities could be inherent to
this strain of chickens without having been reported
previously.
No lesions were observed in the central or peripheral
nervous system that were significant either in terms of
transmission of BSE or the clinical neurological signs
observed. The vacuolation observed in the central ner-
vous system of both the chickens and mice is most
probably age and or host strain related.
Using biochemical extraction and PK digestion techni-
ques, identical or similar to the one used in this study,
SAF have been detected in a wide range of prion dis-
eases, both natural and experimental [2,5,16,32-41]. SAF
are considered to be aggregates of the abnormal prion
protein and, prior to the routine introduction of
immunochemical methods for the detection of the pro-
tein, were the most studied pathological marker for the
TSE [42]. The detection of SAF in the diagnosis of
mammalian TSE has been shown to be a relatively
insensitive approach but unlike immunochemical meth-
ods, provides morphologic detection of the extracted
altered protein, independent of the problems of specifi-
city of immunochemical detection in a species for which
reagents and appropriate control materials are lacking.
Therefore, not withstanding sensitivity issues, negative
results by this method in the present study might be
considered to give more definitive information on the
absence of significant accumulations of an altered form
of the prion protein in central nervous tissue.
No disease-specific immunolabelling was seen with
any of the antibodies used, including 6C2 and R568.
The widespread punctate immunolabelling observed
appear related to technical factors which are largely irre-
solvable in the absence of species and disease specific
antibodies, positive control material and appropriately
developed epitope demasking procedures.
In the present study mammalian derived PrP antibo-
dies were not able to detect abnormal forms of PrP in
the neural tissues of the chicken. Even if it were
assumed that there was successful uptake of infectivity
into nervous tissues there are a number of possible rea-
sons for the failure of the mammalian abnormal prion
protein to initiate a disease process.
The three-dimensional structures of mammalian and
chicken PrP
c are quite similar although there is only
~30% sequence identity [43-45]. The C-terminal domain
of mammalian PrP
c forms a globular domain with a
unique fold which consists of three a-helices and a
short, anti-parallel b-sheet. Chicken PrP
c has a number
of additional structural elements not found in mamma-
lian PrP
c:a3 10 helix between helices 2 and 3, an inser-
tion between helices 2 and 3 which forms a flexibly
disordered loop containing a glycosylation site and elon-
gation of the N-terminal end of helix 3 [43]. The
mechanism of conversion of PrP
c to PrP
Sc is not known
but it is likely that it involves close range interactions
between the two molecules. The additional structural
elements present in chicken PrP
Sc may inhibit or pre-
vent this interaction. For example, changing the charge
distribution at the protein’s surface as occurs in the
Gly200Lys mutation associated with familial Creutzfeldt-
Jakob disease [46], which slows or prevents the propaga-
tion of PrP
d.
The key difference between the structures of the PrP
c
and PrP
Sc isoforms is the relative proportions of a-
helices and b-sheets (reviewed in [47]). Dima and Thiru-
mali [48] showed that the amino acid sequence of helix
2o fc h i c k e nP r P
c has a higher propensity to form a-
helices than the same region of mammalian (mouse)
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c.T h i ss u g g e s t st h a tf o rc h i c k e nP r P
c the transition
from a-helix to b-sheet may not occur as readily as it
does in mammals, or may not occur at all. Therefore,
even if bovine PrP
Sc was able to engage in close range
interactions with chicken PrP
c,i tm a yn o tb ea b l et o
induce the structural transformation which is necessary
for formation of chicken PrP
Sc.
Even assuming successful conversion of chicken PrP
c
into PrP
Sc there is evidence that it lacks key metal-bind-
ing sites which may render it weakly- or non-pathogenic
[49]. In mammalian PrP
c there is a high-affinity copper-
binding site located around His96 [50-53]. This site was
found to be highly conserved in mammals but absent in
the non-mammalian species examined, including
chicken [49]. When copper or other divalent cations are
absent or present at very low levels mammalian PrP
c
becomes more susceptible to proteolytic degradation
and conversion efficiency is reduced (reviewed in [54]).
If the affinity of chicken PrP
c for copper is lower than
in mammals it follows that chicken PrP
Sc would be
more susceptible to proteolytic degradation.
Although in the present study the experimental mod-
els used involved same species sub-passage and wild
type mouse tissue assay after primary exposure to the
BSE agent, it is possible that the chicken, or other avian
species, are susceptible to other TSE agents after parent-
eral exposure. In a study where chickens were intrave-
nously inoculated with a TME agent passaged in mink
[55] putatively small amounts of infectivity were recov-
ered by mink bioassay from chicken lymphoreticular tis-
sues sampled at 30 and 148 days p.i. but the chickens
did not show any neurological signs or pathological
changes in the brain. No other diagnostic studies of the
chickens’ tissues were performed. It is unclear whether
this observation was related to uptake and persistence of
inoculum, or replication of agent in the tissues.
Conclusion
The present study addressed only the potential for the
development of disease in the domestic chicken due to
the BSE agent after parenteral or per os administration.
Questions as to the possibilities of the uptake of inocu-
lum into cells and whether infection can occur with a
resultant sub-clinical state from exposure to TSE agents
requires different approaches and highly sensitive spe-
cies-specific immunochemical techniques, although the
negative results of sub-passage experiments conducted
in this study do not suggest establishment or persistence
of infectivity in the donor tissues. The sequence of avian
PrP is highly conserved among the avian species which
have been tested and which are used for food, including
pigeon [56], duck [57], quail [56] and peacock [57]. It is
therefore unlikely that BSE could be successfully trans-
mitted to these species.
Additional material
Additional file 1: Female chicken, number 979, at 1270 days post
parenteral inoculation (primary exposure study). It is first seen
feeding from a trough (time 8:40 is displayed in the left bottom corner
of the clip). It then retreats with its eyes closed and appears to sleep,
sitting down with its head resting on the side of the trough. At 8:44, it
wakes up, moves its head and gets up before feeding again from the
trough.
Additional file 2: Female chicken, number 980, at 1256 days post
parenteral inoculation (primary exposure study). This chicken has
difficulty maintaining balance as can be seen when it is pushed to the
side or encouraged to move. It is generally reluctant to walk and has a
tendency to stand with flexed intertarsal joints. By comparison, chicken
989, which was at the same time point post inoculation when filmed
and is shown in the overlaid video clip, walks without difficulty and
stands upright.
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